HLA-B*5701 genetic screening among HIV-1 infected patients in Hong Kong: is this a practical approach in Han-Chinese?

被引：14
|
作者：
To, S. W. C. [1 ]
Chen, J. H. K. [1 ]
Wong, K. H. [2 ]
Chan, K. C. W. [2 ]
Tsang, O. T. Y. [3 ]
Yam, W. C. [1 ]
机构：
[1] Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China
[2] Dept Hlth, Ctr Hlth Protect, Special Prevent Programme, Integrated Treatment Ctr, Hong Kong, Hong Kong, Peoples R China
[3] Princess Margaret Hosp, Dept Med & Geriatr, Hong Kong, Hong Kong, Peoples R China
来源：
INTERNATIONAL JOURNAL OF STD & AIDS | 2013年 / 24卷 / 01期
关键词：
HLA-B*5701; abacavir hypersensitivity; Hong Kong; Han-Chinese; HYPERSENSITIVITY;
D O I：
10.1258/ijsa.2012.012102
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Abacavir hypersensitivity is associated with the presence of human leukocyte antigen (HLA)-allele B*5701. However, the cost and workload of routine HLA-B*5701 pretreatment screening is relatively heavy. This study aimed to determine the prevalence of the HLA-B*5701 allele in the HIV-positive population under care in Hong Kong. Blood samples from 1264 HIV-1 infected patients in Hong Kong were collected between 2007 and 2011 for this study. HLA-B*5701 screening of the study group was determined by in-house polymerase chain reaction (PCR) followed by confirmation using the AlleleSEQR (R) HLA-B PCR/Sequencing Kit (Celera Corporation for Abbott, San Francisco, USA). HLA-B*5701 carriers were identified among 3% of Caucasians, 1% of non-Chinese Asians and 0.5% of Han-Chinese in Hong Kong. Our findings revealed that HLA-B*5701 pretreatment screening might not be necessary for the local Han-Chinese population due to its low prevalence.
引用
收藏
页码：50 / 52
页数：3
相关论文
共 50 条
  • [21] Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV-infected patients
    Parczewski, M.
    Leszczyszyn-Pynka, M.
    Wnuk, A.
    Urbanska, A.
    Fuksinska, K.
    Bander, D.
    Boron-Kaczmarska, A.
    HIV MEDICINE, 2010, 11 (05) : 345 - 348
  • [22] HLA-associated Polymorphisms of Gag Protein in HIV-1 B' Infected Chinese
    Zou, Sen
    Hao, Jinjuan
    Chen, Yanli
    Qi, Zhongwei
    Hu, Yuanyuan
    Ruan, Yuhua
    Hong, Kunxue
    Shao, Yiming
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 : 272 - 272
  • [23] FREQUENCY OF HLA-B*57:01 ALLELE IN HIV-INFECTED PATIENTS AND SCREENING FOR ABACAVIR THERAPY
    Giuliodori, Silvia
    Lamanna, Roberta
    Benecchi, Magda
    Zanelli, Paola
    HLA, 2017, 89 (06) : 471 - 472
  • [24] Host correlates distinguish low-risk and high-risk HIV-1 disease progression in HLA-B☆5701 individuals
    Raposo, Andre
    Abdel-Mohsen, Mohamed
    Hecht, Frederick
    Pilcher, Christopher
    Pillai, Satish
    Nixon, Douglas
    JOURNAL OF IMMUNOLOGY, 2013, 190
  • [25] Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir
    Mallal, S
    Nolan, D
    Witt, C
    Masel, G
    Martin, AM
    Moore, C
    Sayer, D
    Castley, A
    Mamotte, C
    Maxwell, D
    James, I
    Christiansen, FT
    LANCET, 2002, 359 (9308): : 727 - 732
  • [26] HLA-B, HLA-DRB1 and TNF-α allele frequencies in Mexican Mestizo HIV-1 patients
    Zúniga, J
    Quiroz-Morales, V
    Flores, E
    Alvarado, D
    Vargas-Alarcón, G
    Granados, J
    Reyes-Terán, G
    TISSUE ANTIGENS, 2002, 59 : 121 - 121
  • [27] Influence of HLA-B*5701 on 20 year survival rate among patients living with HIV (vol 16, e0255834, 2021)
    Aksak-Was, Bogusz Jan
    Parczewski, Milosz
    Urbanska, Anna
    Hackiewicz, Malgorzata
    Kowalska, Justyna D.
    PLOS ONE, 2022, 17 (08):
  • [28] HLA - B 17 Prevalence in HIV-1 Infected Patients under Antiretroviral Treatment
    Shankarkumar, U.
    Shankarkumar, A.
    INTERNATIONAL JOURNAL OF HUMAN GENETICS, 2011, 11 (01) : 59 - 62
  • [29] Multi-centre prospective study (PEPI) of HLA-B*5701 prevalence in HIV-infected French patients by one central and 24 local laboratories
    Gautreau, C.
    Vinatier, I.
    Cesbron-Gautier, A.
    Caillat-Zucman, S.
    Nachbaur, G.
    Roche, C.
    Hadacek, B.
    Charron, D.
    Molina, J. M.
    TISSUE ANTIGENS, 2008, 71 (04): : 364 - 364
  • [30] Very early ART resulting in the absence of HIV-1 antibodies and in a sustained undetectable plasma HIV-1-RNA and proviral-DNA in an HLA-B*5701 and Δ32 heterozygote HIV-1-infected patient was not associated with functional cure
    Calin, Ruxandra
    Fourati, Slim
    Schneider, Luminita
    Gautheret-Dejean, Agnes
    Lambert-Niclot, Sidonie
    Wirden, Marc
    Carcelain, Guislaine
    Katlama, Christine
    Marcelin, Anne-Genevieve
    Tubiana, Roland
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (01) : 317 - 319
12345